Ruiliang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ruiliang Wang has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Bin Yang
Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
19 shared publications - Changcheng Guo
Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
19 shared publications - Tingting Zhao
School of Life Sciences and Technology, Tongji University, Shanghai, China
19 shared publications - Chengqi Jin
Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
18 shared publications - Chenyi Zhu
Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
18 shared publications - Jing Xu
Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
18 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Pseudomonas aeruginosa Exacerbates Bladder Cancer Progression by Activating Cancer-Driven Immunosuppression
Bladder cancer cells recruit MDSCs during P. aeruginosa infection
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Pseudomonas aeruginosa Exacerbates Bladder Cancer Progression by Activating Cancer-Driven Immunosuppression
Bladder cancer cells recruit MDSCs during P. aeruginosa infection
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Pseudomonas aeruginosa Exacerbates Bladder Cancer Progression by Activating Cancer-Driven Immunosuppression
P. aeruginosa infection exacerbates bladder cancer progression
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Pseudomonas aeruginosa Exacerbates Bladder Cancer Progression by Activating Cancer-Driven Immunosuppression
P. aeruginosa infection exacerbates bladder cancer progression
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Pseudomonas aeruginosa Exacerbates Bladder Cancer Progression by Activating Cancer-Driven Immunosuppression
Pseudomonas aeruginosa infection is still a serious problem among immunocompromised patients who have advanced urinary tract malignancies, yet the impact of P. aeruginosa on disease progression remains poorly defined. In this study, we show that urinary tract infections caused by P. aeruginosa exacerbated bladder cancer progression in murine models, primarily by inducing an immunosuppressive tumor microenvironment. Mechanistically, P. aeruginosa activated Toll-like receptor 5 (TLR5) on bladder cancer cells, triggering phosphorylation of ERK1/2 and subsequent secretion of the chemokine CCL20. This signaling axis promoted the recruitment of myeloid-derived suppressor cells (MDSC), thereby reinforcing immunosuppression within the tumor microenvironment and exacerbating bladder cancer growth. In clinical samples, 16S rRNA sequencing and transcriptome analysis of bladder cancer tissues confirmed the presence of P. aeruginosa, with its abundance significantly correlating with advanced disease stages and elevated CCL20 expression. Collectively, these data identify a role for P. aeruginosa in promoting bladder cancer progression through TLR5–ERK1/2–CCL20–mediated MDSC recruitment, shedding light on the intricate interplay between microbial infection and cancer pathogenesis. These insights highlight potential therapeutic targets to disrupt infection-driven cancer progression.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Pseudomonas aeruginosa Exacerbates Bladder Cancer Progression by Activating Cancer-Driven Immunosuppression
Pseudomonas aeruginosa infection is still a serious problem among immunocompromised patients who have advanced urinary tract malignancies, yet the impact of P. aeruginosa on disease progression remains poorly defined. In this study, we show that urinary tract infections caused by P. aeruginosa exacerbated bladder cancer progression in murine models, primarily by inducing an immunosuppressive tumor microenvironment. Mechanistically, P. aeruginosa activated Toll-like receptor 5 (TLR5) on bladder cancer cells, triggering phosphorylation of ERK1/2 and subsequent secretion of the chemokine CCL20. This signaling axis promoted the recruitment of myeloid-derived suppressor cells (MDSC), thereby reinforcing immunosuppression within the tumor microenvironment and exacerbating bladder cancer growth. In clinical samples, 16S rRNA sequencing and transcriptome analysis of bladder cancer tissues confirmed the presence of P. aeruginosa, with its abundance significantly correlating with advanced disease stages and elevated CCL20 expression. Collectively, these data identify a role for P. aeruginosa in promoting bladder cancer progression through TLR5–ERK1/2–CCL20–mediated MDSC recruitment, shedding light on the intricate interplay between microbial infection and cancer pathogenesis. These insights highlight potential therapeutic targets to disrupt infection-driven cancer progression.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Pseudomonas aeruginosa Exacerbates Bladder Cancer Progression by Activating Cancer-Driven Immunosuppression
Bladder cancer cells recruit MDSCs during P. aeruginosa infection
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Pseudomonas aeruginosa Exacerbates Bladder Cancer Progression by Activating Cancer-Driven Immunosuppression
Bladder cancer cells recruit MDSCs during P. aeruginosa infection
- 9 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (3) , 387-398
Pseudomonas aeruginosa Exacerbates Bladder Cancer Progression by Activating Cancer-Driven Immunosuppression
Pseudomonas aeruginosa infection is still a serious problem among immunocompromised patients who have advanced urinary tract malignancies, yet the impact of P. aeruginosa on disease progression remains poorly defined. In this study, we show that urinary tract infections caused by P. aeruginosa exacerbated bladder cancer progression in murine models, primarily by inducing an immunosuppressive tumor microenvironment. Mechanistically, P. aeruginosa activated Toll-like receptor 5 (TLR5) on bladder cancer cells, triggering phosphorylation of ERK1/2 and subsequent secretion of the chemokine CCL20. This signaling axis promoted the recruitment of myeloid-derived suppressor cells (MDSC), thereby reinforcing immunosuppression within the tumor microenvironment and exacerbating bladder cancer growth. In clinical samples, 16S rRNA sequencing and transcriptome analysis of bladder cancer tissues confirmed the presence of P. aeruginosa, with its abundance significantly correlating with advanced disease stages and elevated CCL20 expression. Collectively, these data identify a role for P. aeruginosa in promoting bladder cancer progression through TLR5–ERK1/2–CCL20–mediated MDSC recruitment, shedding light on the intricate interplay between microbial infection and cancer pathogenesis. These insights highlight potential therapeutic targets to disrupt infection-driven cancer progression.
- 9 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (3) , 387-398
Pseudomonas aeruginosa Exacerbates Bladder Cancer Progression by Activating Cancer-Driven Immunosuppression
Pseudomonas aeruginosa infection is still a serious problem among immunocompromised patients who have advanced urinary tract malignancies, yet the impact of P. aeruginosa on disease progression remains poorly defined. In this study, we show that urinary tract infections caused by P. aeruginosa exacerbated bladder cancer progression in murine models, primarily by inducing an immunosuppressive tumor microenvironment. Mechanistically, P. aeruginosa activated Toll-like receptor 5 (TLR5) on bladder cancer cells, triggering phosphorylation of ERK1/2 and subsequent secretion of the chemokine CCL20. This signaling axis promoted the recruitment of myeloid-derived suppressor cells (MDSC), thereby reinforcing immunosuppression within the tumor microenvironment and exacerbating bladder cancer growth. In clinical samples, 16S rRNA sequencing and transcriptome analysis of bladder cancer tissues confirmed the presence of P. aeruginosa, with its abundance significantly correlating with advanced disease stages and elevated CCL20 expression. Collectively, these data identify a role for P. aeruginosa in promoting bladder cancer progression through TLR5–ERK1/2–CCL20–mediated MDSC recruitment, shedding light on the intricate interplay between microbial infection and cancer pathogenesis. These insights highlight potential therapeutic targets to disrupt infection-driven cancer progression.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Multivariate Analysis of Prognostic Factors Based on Tumor Tissue
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Multivariate Analysis of Prognostic Factors Based on Tumor Tissue
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Clinical Data Correlated with Genomic Alterations
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Clinical Data Correlated with Genomic Alterations